Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05219929 · ClinicalTrials.gov registry record · Phase 2
Tetracycline Treatment Tolerability Trial
A Phase 2 study, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
NCT05219929: Completed Phase 2 study, sponsored by Johns Hopkins University.
NCT05219929 is a Phase 2 study that has completed, run by Johns Hopkins University. The registered enrollment target is 60 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05219929, a Phase 2 study, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
Study Summary
Randomized, double-blind, placebo-controlled study (with a one-week washout period) where subjects receive either 3 months of tetracycline or 3 months of placebo. After the 3 month primary endpoint, in the follow-up period, patients will be assigned to the alternate treatment for 3 months with blind maintained.
Interventions
- OTHER Placebo
- DRUG Tetracycline 500 Mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2022-11-02 |
| Est. Completion | 2026-06-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05219929
The ClinicalTrials.gov registry entry for NCT05219929 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05219929 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05219929 about?
NCT05219929 is a clinical study titled "Tetracycline Treatment Tolerability Trial". Randomized, double-blind, placebo-controlled study (with a one-week washout period) where subjects receive either 3 months of tetracycline or 3 months of placebo. After the 3 month primary endpoint, in the follow-up period, patients will be assigned to the alternate treatment for 3 months with blind...
What is the current status of trial NCT05219929?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2022-11-02. Estimated completion is 2026-06-09.
What interventions are being tested in trial NCT05219929?
The interventions under investigation include: Placebo (OTHER), Tetracycline 500 Mg (DRUG).
Who is sponsoring clinical trial NCT05219929?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.